Tenofovir disoproxil fumarate

Generic Medicine Info
Hypersensitivity. Lactation.
Special Precautions
Patient with risk factors for liver disease; coinfection with HIV and HBV. Renal and hepatic impairment. Pregnancy. Patient Counselling This drug may cause dizziness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor renal function and serum phosphate concentrations before the start of therapy, within the first 4 weeks of treatment, after 3 months of treatment, and every 3-6 months thereafter; bone density at baseline and during treatment; LFT every 3 months during therapy and for several months following discontinuation. Determine HIV status in all hepatitis B virus (HBV) infected patients prior to treatment.
Adverse Reactions
Significant: Decreased bone mineral density, immune reconstitution syndrome, osteomalacia with proximal renal tubulopathy, acute renal failure and/or Fanconi syndrome. Gastrointestinal disorders: Diarrhoea, vomiting, nausea, abdominal pain, abdominal distention, flatulence. General disorders and administration site conditions: Asthenia, fatigue, fever. Metabolism and nutrition disorders: Hypophosphataemia. Nervous system disorders: Dizziness, headache. Psychiatric disorders: Insomnia, depression. Skin and subcutaneous tissue disorders: Rash, urticaria, pruritus.
Potentially Fatal: Lactic acidosis, severe hepatomegaly with steatosis.
Drug Interactions
May decrease the plasma concentrations of atazanavir and increased plasma concentration of tenofovir disoproxil fumarate when given concomitantly. May increase the plasma concentrations of didanosine. Increased risk of nephrotoxicity with drugs that reduce renal function (e.g. cidofovir, aminoglycosides, amphotericin B, foscarnet, ganciclovir, pentamidine, vancomycin). Decreased therapeutic effect with adefovir.
CIMS Class
Disclaimer: This information is independently developed by CIMS based on tenofovir disoproxil fumarate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in